Patent intelligence · US
US 6936731
Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
Patent details — US 6936731
- Jurisdiction
- US
- Status
- expired
- Grant date
- Aug 30, 2005
- Expiration
- Aug 25, 2025
- Applicant
- TEVA Gyógyszergyár Részvénytársaság
- Claims
- 9
- CPC classes
- A61K, A61K31/225
Quick answer
US 6936731 (Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same) is held by TEVA Gyógyszergyár Részvénytársaság. Status: expired. Granted Aug 30, 2005. Expires Aug 25, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TEVA Gyógyszergyár Részvénytársaság
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K31/225
More from TEVA Gyógyszergyár Részvénytársaság
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Frequently asked questions
What is US patent 6936731?
US 6936731 (Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same) is held by TEVA Gyógyszergyár Részvénytársaság. Status: expired. Granted Aug 30, 2005. Expires Aug 25, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6936731?
TEVA Gyógyszergyár Részvénytársaság is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 6936731 expire?
Our index shows an expiration date of Aug 25, 2025 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.